Bleomycin pharmacokinetics in man - I. Intravenous administration

David S Alberts, H. S G Chen, Rosa Liu, K. J. Himmelstein, Michael Mayersohn, D. Perrier, J. Gross, T. Moon, A. Broughton, S. E. Salmon

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Bleomycin plasma decay kinetics and urinary excretion were studied in nine patients after IV bolus injections of 13.7 to 19.9 U/M<sup>2</sup>. Radio-immunoassay was used to measure bleomycin in plasma and urine samples. The resulting plasma concentration versus time data for each patient and the combined data obtained from all patients were fitted to a multiexponential equation using a nonlinear regression computer program. Pharmacokinetic parameters derived from the mean of all individual patient parameters and the composite of all plasma decay data were similar. Bleomycin initial and terminal plasma half-lives and volume of distribution for all plasma decay data from eight patients with normal serum creatinies were 24.4±4.0 min, 237.5±8.5 min, and 17.3±1.5 L/M<sup>2</sup>, respectively. Mean 24-h urinary excretion accounted for 44.8±12.6% of the dose in seven patients who had normal serum creatinine values and complete urine collections. The total body clearance and renal clearance in these seven patients averaged 50.5±4.1 ml/min/M<sup>2</sup> and 23.0±1.9 ml/min/M<sup>2</sup>, respectively. One patient with a serum creatinine of 1.5 mg% (normal 0.7 to 1.3 mg%) who was given 15.6 U/M<sup>2</sup> had a terminal plasma halflife of 624 min, a volume of distribution of 36.3 L/M<sup>2</sup>, and 24-h urinary excretion of 11.6% of the dose. We conclude that bleomycin after intravenous bolus injection has a relatively short terminal phase plasma halflife and relatively large urinary elimination.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume1
Issue number3
DOIs
StatePublished - 1978

Fingerprint

Pharmacokinetics
Intravenous Administration
Plasmas
Bleomycin
Half-Life
Creatinine
Serum
Urine Specimen Collection
indium-bleomycin
Radio
Immunoassay
Intravenous Injections
Computer program listings
Software
Urine
Kidney
Injections
Kinetics
Composite materials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Bleomycin pharmacokinetics in man - I. Intravenous administration. / Alberts, David S; Chen, H. S G; Liu, Rosa; Himmelstein, K. J.; Mayersohn, Michael; Perrier, D.; Gross, J.; Moon, T.; Broughton, A.; Salmon, S. E.

In: Cancer Chemotherapy and Pharmacology, Vol. 1, No. 3, 1978, p. 177-181.

Research output: Contribution to journalArticle

Alberts, DS, Chen, HSG, Liu, R, Himmelstein, KJ, Mayersohn, M, Perrier, D, Gross, J, Moon, T, Broughton, A & Salmon, SE 1978, 'Bleomycin pharmacokinetics in man - I. Intravenous administration', Cancer Chemotherapy and Pharmacology, vol. 1, no. 3, pp. 177-181. https://doi.org/10.1007/BF00253118
Alberts, David S ; Chen, H. S G ; Liu, Rosa ; Himmelstein, K. J. ; Mayersohn, Michael ; Perrier, D. ; Gross, J. ; Moon, T. ; Broughton, A. ; Salmon, S. E. / Bleomycin pharmacokinetics in man - I. Intravenous administration. In: Cancer Chemotherapy and Pharmacology. 1978 ; Vol. 1, No. 3. pp. 177-181.
@article{3bf3f9fa43f94d0e8041c2687e76c932,
title = "Bleomycin pharmacokinetics in man - I. Intravenous administration",
abstract = "Bleomycin plasma decay kinetics and urinary excretion were studied in nine patients after IV bolus injections of 13.7 to 19.9 U/M2. Radio-immunoassay was used to measure bleomycin in plasma and urine samples. The resulting plasma concentration versus time data for each patient and the combined data obtained from all patients were fitted to a multiexponential equation using a nonlinear regression computer program. Pharmacokinetic parameters derived from the mean of all individual patient parameters and the composite of all plasma decay data were similar. Bleomycin initial and terminal plasma half-lives and volume of distribution for all plasma decay data from eight patients with normal serum creatinies were 24.4±4.0 min, 237.5±8.5 min, and 17.3±1.5 L/M2, respectively. Mean 24-h urinary excretion accounted for 44.8±12.6{\%} of the dose in seven patients who had normal serum creatinine values and complete urine collections. The total body clearance and renal clearance in these seven patients averaged 50.5±4.1 ml/min/M2 and 23.0±1.9 ml/min/M2, respectively. One patient with a serum creatinine of 1.5 mg{\%} (normal 0.7 to 1.3 mg{\%}) who was given 15.6 U/M2 had a terminal plasma halflife of 624 min, a volume of distribution of 36.3 L/M2, and 24-h urinary excretion of 11.6{\%} of the dose. We conclude that bleomycin after intravenous bolus injection has a relatively short terminal phase plasma halflife and relatively large urinary elimination.",
author = "Alberts, {David S} and Chen, {H. S G} and Rosa Liu and Himmelstein, {K. J.} and Michael Mayersohn and D. Perrier and J. Gross and T. Moon and A. Broughton and Salmon, {S. E.}",
year = "1978",
doi = "10.1007/BF00253118",
language = "English (US)",
volume = "1",
pages = "177--181",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Bleomycin pharmacokinetics in man - I. Intravenous administration

AU - Alberts, David S

AU - Chen, H. S G

AU - Liu, Rosa

AU - Himmelstein, K. J.

AU - Mayersohn, Michael

AU - Perrier, D.

AU - Gross, J.

AU - Moon, T.

AU - Broughton, A.

AU - Salmon, S. E.

PY - 1978

Y1 - 1978

N2 - Bleomycin plasma decay kinetics and urinary excretion were studied in nine patients after IV bolus injections of 13.7 to 19.9 U/M2. Radio-immunoassay was used to measure bleomycin in plasma and urine samples. The resulting plasma concentration versus time data for each patient and the combined data obtained from all patients were fitted to a multiexponential equation using a nonlinear regression computer program. Pharmacokinetic parameters derived from the mean of all individual patient parameters and the composite of all plasma decay data were similar. Bleomycin initial and terminal plasma half-lives and volume of distribution for all plasma decay data from eight patients with normal serum creatinies were 24.4±4.0 min, 237.5±8.5 min, and 17.3±1.5 L/M2, respectively. Mean 24-h urinary excretion accounted for 44.8±12.6% of the dose in seven patients who had normal serum creatinine values and complete urine collections. The total body clearance and renal clearance in these seven patients averaged 50.5±4.1 ml/min/M2 and 23.0±1.9 ml/min/M2, respectively. One patient with a serum creatinine of 1.5 mg% (normal 0.7 to 1.3 mg%) who was given 15.6 U/M2 had a terminal plasma halflife of 624 min, a volume of distribution of 36.3 L/M2, and 24-h urinary excretion of 11.6% of the dose. We conclude that bleomycin after intravenous bolus injection has a relatively short terminal phase plasma halflife and relatively large urinary elimination.

AB - Bleomycin plasma decay kinetics and urinary excretion were studied in nine patients after IV bolus injections of 13.7 to 19.9 U/M2. Radio-immunoassay was used to measure bleomycin in plasma and urine samples. The resulting plasma concentration versus time data for each patient and the combined data obtained from all patients were fitted to a multiexponential equation using a nonlinear regression computer program. Pharmacokinetic parameters derived from the mean of all individual patient parameters and the composite of all plasma decay data were similar. Bleomycin initial and terminal plasma half-lives and volume of distribution for all plasma decay data from eight patients with normal serum creatinies were 24.4±4.0 min, 237.5±8.5 min, and 17.3±1.5 L/M2, respectively. Mean 24-h urinary excretion accounted for 44.8±12.6% of the dose in seven patients who had normal serum creatinine values and complete urine collections. The total body clearance and renal clearance in these seven patients averaged 50.5±4.1 ml/min/M2 and 23.0±1.9 ml/min/M2, respectively. One patient with a serum creatinine of 1.5 mg% (normal 0.7 to 1.3 mg%) who was given 15.6 U/M2 had a terminal plasma halflife of 624 min, a volume of distribution of 36.3 L/M2, and 24-h urinary excretion of 11.6% of the dose. We conclude that bleomycin after intravenous bolus injection has a relatively short terminal phase plasma halflife and relatively large urinary elimination.

UR - http://www.scopus.com/inward/record.url?scp=0018055545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018055545&partnerID=8YFLogxK

U2 - 10.1007/BF00253118

DO - 10.1007/BF00253118

M3 - Article

VL - 1

SP - 177

EP - 181

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -